ELECTRICAL STIMULATION ON ORGANIC CONDUCTORS
With
Distinguished Professor Gordon Wallace AO,
Executive Research Director
Intelligent Polymer Research Institute (IPRI)
University of Wollongong, New South Wales, Australia
RESEARCHER PROFILE
Filmed in Wollongong, New South Wales, Australia | November 2025
Professor Gordon Wallace AO is the Founder and Director of the Intelligent Polymer Research Institute (IPRI) at the University of Wollongong and Founding Director of the Australian National Fabrication Facility (ANFF) Materials Node. He was previously the Executive Director of the ARC Centre of Excellence for Electromaterials Science (ACES).
He was awarded an ARC Laureate Fellowship in Nanobionics in 2011, appointed as an Officer of the Order of Australia (AO) for his commitment to research collaboration and innovation in 2017, elected as a Fellow, Royal Society of NSW in 2017, and appointed to Prime Ministers Knowledge Nation 100 in 2015. He was elected to the Royal Irish Academy in 2022.
Over his career, Professor Wallace has attracted over $100M in competitive funding and his team was awarded an ARC Centre ($7.3M over 5 years) in 2003, which was subsequently upgraded in 2005 to an ARC Centre of Excellence ($14M over 5 years). A 3-year extension ($7.5M) of this Centre was awarded in 2010.
In 2014 he led a team successful in attracting a further 7 years ($25M) funding to ACES. This core funding has been supplemented by an ARC Federation Fellowship and Laureate Fellowship, ARC and NHMRC project grants, CRC projects (CRC Polymer a,CRC Hearing and Marine Bioproducts CRC), funding from the Defence Advanced Research Program Agency (USA), CSIRO, DSTO, the NSW Government and recently MTP Connect and ARENA.
In 2009, he was instrumental in attracting $50M in Federal Government funding to establish a Materials Processing and Device Fabrication Facility at UOW. To date, he is the Chief Scientist on the ($35M) BIENCO project and belongs on the Executive Committee Board alongside BIENCO CEO Danielle Fisher and Project Lead Gerard Sutton.
Since 2023, Intelligent Polymer Research Institute (IPRI) has also been a crucial member of BIENCO, a world-first consortium of clinical practitioners, researchers and bioengineers addressing the global challenge of corneal blindness. He has published in excess of 1,200 refereed journal publications that have attracted more than 72,000 citations with an H-index of 123 (Scopus).He is named as a co-inventor on more than 60 patents. He is the lead author on three monographs entitled “Organic Bionics” (Wiley- VCH 2012), “Intelligent Polymer Systems” and “3D Bioprinting: Printing Parts for Bodies” (2014) and has also authored an additional 38 book chapters.
Source: Supplied
https://orcid.org/0000-0002-0381-7273
-
Genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia
Prof Deborah White’s research focus is genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia (ALL) and Chronic Myeloid Leukaemia (CML) and she holds peer reviewed grants from: The William Lawrence and Blanche Hughes Foundation and the Leukemia Lymphoma Society (USA), the NHMRC, the Leukaemia Foundation Australia (LFA), Channel 7, Cancer Australia, Tour de Cure and the Cancer Council SA (CCSA). Professor White has presented more than 170 papers at scientific meetings, and authored more than 100 scientific publications as well as being an inventor on several international patents.
-
Exercise therapy for metabolic dysfunction-associated steatotic liver disease
Dr Shelley Keating is a Senior Lecturer in Clinical Exercise Physiology and Accredited Exercise Physiologist from the School of Human Movement and Nutrition Sciences at the University of Queensland. With a strong grounding in exercise metabolism and body composition, Dr Keating’s research centres on the utility of exercise as a therapy for obesity and related cardiometabolic conditions, notably metabolic dysfunction-associated steatotic liver disease (MASLD).
-
Applying artificial intelligence to medical imaging for cardiovascular disease detection
Parmida is a software engineer and biomedical scientist whose research focuses on translating novel medical imaging technologies into clinical practice to improve the diagnosis and management of cardiovascular disease.
Her current work applies advanced deep learning techniques to retinal polarization-sensitive optical coherence tomography (PS-OCT) imaging, aiming to generate clinically meaningful biomarkers and predictions of cardiovascular disease. Parmida’s collaboration partners include Fiona Stanley Hospital in Murdoch, Western Australia.
